Brief Report: HIV Drug Resistance in Adults Failing Early Antiretroviral Treatment: Results from the HIV Prevention Trials Network 052 Trial: HIV Drug Resistance in Adults Failing Early Antiretroviral Treatment: Results from the HIV Prevention Trials Network 052 Trial

Jessica M. Fogel; Sarah E. Hudelson; San San Ou; Stephen Hart; Carole Wallis; Mariza G. Morgado; Shanmugam Saravanan; Srikanth Tripathy; Laura Hovind; Estelle Piwowar-Manning; Devin Sabin; Marybeth McCauley; Theresa Gamble; Xinyi C. Zhang; Joseph J. Eron; Joel E. Gallant; Johnstone Kumwenda; Joseph Makhema; Nagalingeswaran Kumarasamy; Suwat Chariyalertsak; James Hakim; Sharlaa Badal-Faesen; Victor Akelo; Mina C. Hosseinipour; Breno R. Santos; Sheela V. Godbole; Jose H. Pilotto; Beatriz Grinsztejn; Ravindre Panchia; Kenneth H. Mayer; Ying Q. Chen; Myron S. Cohen; Susan H. Eshleman

doi:10.1097/qai.0000000000000951

Brief Report: HIV Drug Resistance in Adults Failing Early Antiretroviral Treatment: Results from the HIV Prevention Trials Network 052 Trial: HIV Drug Resistance in Adults Failing Early Antiretroviral Treatment: Results from the HIV Prevention Trials Network 052 Trial

Jessica M. Fogel
, Sarah E. Hudelson
, San San Ou
, Stephen Hart
, Carole Wallis
, Mariza G. Morgado
, Shanmugam Saravanan
, Srikanth Tripathy
, Laura Hovind
, Estelle Piwowar-Manning
, Devin Sabin
, Marybeth McCauley
, Theresa Gamble
, Xinyi C. Zhang
, Joseph J. Eron
, Joel E. Gallant
, Johnstone Kumwenda
, Joseph Makhema
, Nagalingeswaran Kumarasamy
, Suwat Chariyalertsak

James Hakim, Sharlaa Badal-Faesen, Victor Akelo, Mina C. Hosseinipour, Breno R. Santos, Sheela V. Godbole, Jose H. Pilotto, Beatriz Grinsztejn, Ravindre Panchia, Kenneth H. Mayer, Ying Q. Chen, Myron S. Cohen, Susan H. Eshleman

Johns Hopkins University
Fred Hutchinson Cancer Research Center
Frontier Science & Technology Research Foundation
Lancet Laboratories
Fundação Oswaldo Cruz
Y.R. Gaitonde Centre for AIDS Research and Education
National Jalma Institute of Leprosy and Other Mycobacterial Diseases
FHI 360
University of North Carolina at Chapel Hill
Southwest CARE Center
University of Malawi
Botswana-Harvard AIDS Institute Partnership
VHS Medical Centre India
Chiang Mai University
University of Zimbabwe
University of the Witwatersrand
Kenya Medical Research Institute
Hospital Nossa Senhora da Conceição
Indian Council of Medical Research
Hospital Geral de Nova Iguacu and Laboratorio de AIDS e Imunologia Molecular-IOC/Fiocruz
Fenway Community Health Center
Harvard University

Research output: Contribution to journal › Article › peer-review

15 Citations (Scopus)

Abstract

Early initiation of antiretroviral treatment (ART) reduces HIV transmission and has health benefits. HIV drug resistance can limit treatment options and compromise use of ART for HIV prevention. We evaluated drug resistance in 85 participants in the HIV Prevention Trials Network 052 trial who started ART at CD4 counts of 350-550 cells per cubic millimeter and failed ART by May 2011; 8.2% had baseline resistance and 35.3% had resistance at ART failure. High baseline viral load and less education were associated with emergence of resistance at ART failure. Resistance at ART failure was observed in 7 of 8 (87.5%) participants who started ART at lower CD4 cell counts.

Original language	English
Pages (from-to)	304-309
Number of pages	6
Journal	Journal of Acquired Immune Deficiency Syndromes (1999)
Volume	72
Issue number	3
DOIs	https://doi.org/10.1097/qai.0000000000000951
Publication status	Published - 1 Jul 2016
Externally published	Yes

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Keywords

ART failure
early ART
HIV
HPTN 052
resistance

Access to Document

10.1097/qai.0000000000000951

Fingerprint

Dive into the research topics of 'Brief Report: HIV Drug Resistance in Adults Failing Early Antiretroviral Treatment: Results from the HIV Prevention Trials Network 052 Trial: HIV Drug Resistance in Adults Failing Early Antiretroviral Treatment: Results from the HIV Prevention Trials Network 052 Trial'. Together they form a unique fingerprint.

Cite this

Fogel, J. M., Hudelson, S. E., Ou, S. S., Hart, S., Wallis, C., Morgado, M. G., Saravanan, S., Tripathy, S., Hovind, L., Piwowar-Manning, E., Sabin, D., McCauley, M., Gamble, T., Zhang, X. C., Eron, J. J., Gallant, J. E., Kumwenda, J., Makhema, J., Kumarasamy, N., ... Eshleman, S. H. (2016). Brief Report: HIV Drug Resistance in Adults Failing Early Antiretroviral Treatment: Results from the HIV Prevention Trials Network 052 Trial: HIV Drug Resistance in Adults Failing Early Antiretroviral Treatment: Results from the HIV Prevention Trials Network 052 Trial. Journal of Acquired Immune Deficiency Syndromes (1999), 72(3), 304-309. https://doi.org/10.1097/qai.0000000000000951

Fogel, Jessica M. ; Hudelson, Sarah E. ; Ou, San San et al. / Brief Report: HIV Drug Resistance in Adults Failing Early Antiretroviral Treatment: Results from the HIV Prevention Trials Network 052 Trial: HIV Drug Resistance in Adults Failing Early Antiretroviral Treatment: Results from the HIV Prevention Trials Network 052 Trial. In: Journal of Acquired Immune Deficiency Syndromes (1999). 2016 ; Vol. 72, No. 3. pp. 304-309.

@article{579e8494ba9c49bca9ea322bf608857d,

title = "Brief Report: HIV Drug Resistance in Adults Failing Early Antiretroviral Treatment: Results from the HIV Prevention Trials Network 052 Trial: HIV Drug Resistance in Adults Failing Early Antiretroviral Treatment: Results from the HIV Prevention Trials Network 052 Trial",

abstract = "Early initiation of antiretroviral treatment (ART) reduces HIV transmission and has health benefits. HIV drug resistance can limit treatment options and compromise use of ART for HIV prevention. We evaluated drug resistance in 85 participants in the HIV Prevention Trials Network 052 trial who started ART at CD4 counts of 350-550 cells per cubic millimeter and failed ART by May 2011; 8.2\% had baseline resistance and 35.3\% had resistance at ART failure. High baseline viral load and less education were associated with emergence of resistance at ART failure. Resistance at ART failure was observed in 7 of 8 (87.5\%) participants who started ART at lower CD4 cell counts.",

keywords = "ART failure, early ART, HIV, HPTN 052, resistance",

author = "Fogel, \{Jessica M.\} and Hudelson, \{Sarah E.\} and Ou, \{San San\} and Stephen Hart and Carole Wallis and Morgado, \{Mariza G.\} and Shanmugam Saravanan and Srikanth Tripathy and Laura Hovind and Estelle Piwowar-Manning and Devin Sabin and Marybeth McCauley and Theresa Gamble and Zhang, \{Xinyi C.\} and Eron, \{Joseph J.\} and Gallant, \{Joel E.\} and Johnstone Kumwenda and Joseph Makhema and Nagalingeswaran Kumarasamy and Suwat Chariyalertsak and James Hakim and Sharlaa Badal-Faesen and Victor Akelo and Hosseinipour, \{Mina C.\} and Santos, \{Breno R.\} and Godbole, \{Sheela V.\} and Pilotto, \{Jose H.\} and Beatriz Grinsztejn and Ravindre Panchia and Mayer, \{Kenneth H.\} and Chen, \{Ying Q.\} and Cohen, \{Myron S.\} and Eshleman, \{Susan H.\}",

year = "2016",

month = jul,

day = "1",

doi = "10.1097/qai.0000000000000951",

language = "English",

volume = "72",

pages = "304--309",

journal = "Journal of Acquired Immune Deficiency Syndromes (1999)",

issn = "1525-4135",

publisher = "Wolters Kluwer Health",

number = "3",

}

Fogel, JM, Hudelson, SE, Ou, SS, Hart, S, Wallis, C, Morgado, MG, Saravanan, S, Tripathy, S, Hovind, L, Piwowar-Manning, E, Sabin, D, McCauley, M, Gamble, T, Zhang, XC, Eron, JJ, Gallant, JE, Kumwenda, J, Makhema, J, Kumarasamy, N, Chariyalertsak, S, Hakim, J, Badal-Faesen, S, Akelo, V, Hosseinipour, MC, Santos, BR, Godbole, SV, Pilotto, JH, Grinsztejn, B, Panchia, R, Mayer, KH, Chen, YQ, Cohen, MS & Eshleman, SH 2016, 'Brief Report: HIV Drug Resistance in Adults Failing Early Antiretroviral Treatment: Results from the HIV Prevention Trials Network 052 Trial: HIV Drug Resistance in Adults Failing Early Antiretroviral Treatment: Results from the HIV Prevention Trials Network 052 Trial', Journal of Acquired Immune Deficiency Syndromes (1999), vol. 72, no. 3, pp. 304-309. https://doi.org/10.1097/qai.0000000000000951

Brief Report: HIV Drug Resistance in Adults Failing Early Antiretroviral Treatment: Results from the HIV Prevention Trials Network 052 Trial: HIV Drug Resistance in Adults Failing Early Antiretroviral Treatment: Results from the HIV Prevention Trials Network 052 Trial. / Fogel, Jessica M.; Hudelson, Sarah E.; Ou, San San et al.
In: Journal of Acquired Immune Deficiency Syndromes (1999), Vol. 72, No. 3, 01.07.2016, p. 304-309.

Research output: Contribution to journal › Article › peer-review

TY - JOUR

T1 - Brief Report: HIV Drug Resistance in Adults Failing Early Antiretroviral Treatment: Results from the HIV Prevention Trials Network 052 Trial: HIV Drug Resistance in Adults Failing Early Antiretroviral Treatment: Results from the HIV Prevention Trials Network 052 Trial

AU - Fogel, Jessica M.

AU - Hudelson, Sarah E.

AU - Ou, San San

AU - Hart, Stephen

AU - Wallis, Carole

AU - Morgado, Mariza G.

AU - Saravanan, Shanmugam

AU - Tripathy, Srikanth

AU - Hovind, Laura

AU - Piwowar-Manning, Estelle

AU - Sabin, Devin

AU - McCauley, Marybeth

AU - Gamble, Theresa

AU - Zhang, Xinyi C.

AU - Eron, Joseph J.

AU - Gallant, Joel E.

AU - Kumwenda, Johnstone

AU - Makhema, Joseph

AU - Kumarasamy, Nagalingeswaran

AU - Chariyalertsak, Suwat

AU - Hakim, James

AU - Badal-Faesen, Sharlaa

AU - Akelo, Victor

AU - Hosseinipour, Mina C.

AU - Santos, Breno R.

AU - Godbole, Sheela V.

AU - Pilotto, Jose H.

AU - Grinsztejn, Beatriz

AU - Panchia, Ravindre

AU - Mayer, Kenneth H.

AU - Chen, Ying Q.

AU - Cohen, Myron S.

AU - Eshleman, Susan H.

PY - 2016/7/1

Y1 - 2016/7/1

N2 - Early initiation of antiretroviral treatment (ART) reduces HIV transmission and has health benefits. HIV drug resistance can limit treatment options and compromise use of ART for HIV prevention. We evaluated drug resistance in 85 participants in the HIV Prevention Trials Network 052 trial who started ART at CD4 counts of 350-550 cells per cubic millimeter and failed ART by May 2011; 8.2% had baseline resistance and 35.3% had resistance at ART failure. High baseline viral load and less education were associated with emergence of resistance at ART failure. Resistance at ART failure was observed in 7 of 8 (87.5%) participants who started ART at lower CD4 cell counts.

AB - Early initiation of antiretroviral treatment (ART) reduces HIV transmission and has health benefits. HIV drug resistance can limit treatment options and compromise use of ART for HIV prevention. We evaluated drug resistance in 85 participants in the HIV Prevention Trials Network 052 trial who started ART at CD4 counts of 350-550 cells per cubic millimeter and failed ART by May 2011; 8.2% had baseline resistance and 35.3% had resistance at ART failure. High baseline viral load and less education were associated with emergence of resistance at ART failure. Resistance at ART failure was observed in 7 of 8 (87.5%) participants who started ART at lower CD4 cell counts.

KW - ART failure

KW - early ART

KW - HIV

KW - HPTN 052

KW - resistance

U2 - 10.1097/qai.0000000000000951

DO - 10.1097/qai.0000000000000951

M3 - Article

SN - 1525-4135

VL - 72

SP - 304

EP - 309

JO - Journal of Acquired Immune Deficiency Syndromes (1999)

JF - Journal of Acquired Immune Deficiency Syndromes (1999)

IS - 3

ER -

Fogel JM, Hudelson SE, Ou SS, Hart S, Wallis C, Morgado MG et al. Brief Report: HIV Drug Resistance in Adults Failing Early Antiretroviral Treatment: Results from the HIV Prevention Trials Network 052 Trial: HIV Drug Resistance in Adults Failing Early Antiretroviral Treatment: Results from the HIV Prevention Trials Network 052 Trial. Journal of Acquired Immune Deficiency Syndromes (1999). 2016 Jul 1;72(3):304-309. doi: 10.1097/qai.0000000000000951